Genprex Stock (NASDAQ:GNPX)

Revenue Ownership Financials Chart

Previous Close

$0.63

52W Range

$0.28 - $9.28

50D Avg

$0.97

200D Avg

$1.45

Market Cap

$5.28M

Avg Vol (3M)

$1.18M

Beta

-1.29

Div Yield

GNPX Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 29, 2018

Website

GNPX Performance

GNPX Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	-
Operating Income	$-30.86M	$-23.83M	$-19.60M
Net Income	$-30.86M	$-29.46M	$-19.59M
EBITDA	$-30.86M	$-23.81M	$-19.58M
Basic EPS	$-22.56	$-24.58	$-16.64
Diluted EPS	$-22.56	$-24.58	$-16.64

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
HEPA	Hepion Pharmaceuticals, Inc.
RNAZ	TransCode Therapeutics, Inc.
MREO	Mereo BioPharma Group plc
GLSI	Greenwich LifeSciences, Inc.
EYEN	Eyenovia, Inc.
CGTX	Cognition Therapeutics, Inc.
KOD	Kodiak Sciences Inc.
XFOR	X4 Pharmaceuticals, Inc.
RVPH	Reviva Pharmaceuticals Holdings, Inc.
ELEV	Elevation Oncology, Inc.